AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT by and among FIBROGEN, INC. and its AFFILIATES and ELUMINEX BIOSCIENCES (SUZHOU) LIMITEDExclusive License Agreement • August 7th, 2023 • Fibrogen Inc • Pharmaceutical preparations • New York
This SECOND AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into April 19, 2023 (the “Second Restated License Execution Date”) and effective as of the Effective Date (as defined in Section 1.35), by and among: FIBROGEN, INC., a company organized under the laws of Delaware with a business address at 409 Illinois Street, San Francisco, CA 94158, United States and its Affiliates, including FibroGen (China) Medical Technology Development Co., Ltd. 珐博进（中国）医药技术开发有限公司, a wholly foreign owned limited liability company having its principal place of business at 101-601, Unit 2, Building 7, No. 88, 6th Ke Chuang Street, Beijing Economic Technological Development Area, Beijing, China (“FibroGen China”) (FIBROGEN, INC. and its Affiliates along with FibroGen China are collectively referred to herein as “FIBROGEN”), and ELUMINEX BIOSCIENCES (SUZHOU) LIMITED 典晶生物医药科技（苏州）有限公司, a company organized under the laws of People’s Republic of China with registered address at Unit
Evaluation AGREEMENT BY AND BETWEEN FIBROGEN, INC. AND FORTIS Therapeutics, INC. May 5, 2023Evaluation Agreement • August 7th, 2023 • Fibrogen Inc • Pharmaceutical preparations • Delaware
This Evaluation Agreement (this “Agreement”) is entered into as May 5, 2023 (the “Effective Date”) by and between FIBROGEN, INC., a Delaware corporation, with its principal place of business at 409 Illinois Street, San Francisco, California 94158 (“FibroGen”), and FORTIS THERAPEUTICS, INC., having an address at 11099 North Torrey Pines Road, Suite 290, La Jolla, CA 92037 (“Fortis”). FibroGen and Fortis may be referred to herein individually as a “Party”, or collectively as the “Parties”.
Option Agreement and Plan of Merger BY AND among Fibrogen, Inc., Fortis therapeutics, Inc. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Sellers’ Representative Dated as of MAY 5, 2023Option Agreement and Plan of Merger • August 7th, 2023 • Fibrogen Inc • Pharmaceutical preparations
This Option Agreement and Plan of Merger (this “Option Agreement”) dated as of May 5, 2023, by and among FibroGen, Inc., a Delaware corporation (“FibroGen”), Fortis Therapeutics, Inc., a Delaware corporation (“Fortis”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the Sellers’ Representative.
FINANCING AGREEMENT dated as of April 29, 2023 among FIBROGEN, INC., as Borrower, CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, VARIOUS LENDERS FROM TIME TO TIME PARTY HERETO, AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Administrative AgentFinancing Agreement • August 7th, 2023 • Fibrogen Inc • Pharmaceutical preparations
This FINANCING AGREEMENT, dated as of April 29, 2023, is entered into by and among FIBROGEN, INC., a Delaware corporation (“Company” or “Borrower”), and certain Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party hereto, and Wilmington Trust, National Association (“Wilmington Trust”), as administrative agent for the Lenders (in such capacity, “Administrative Agent”).
